ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Wisconsin » Pulmonary Disease

Top Pulmonary Disease Prescribers in Wisconsin

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
WALEED NAJEEB M.D.

Pulmonary Disease

17,446

$1.37M

552
259 are 65+

20%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 59%

$78
Average prescription price

Avg: $175

SALEH OBAID MD

Pulmonary Disease

11,479

$791K

427
380 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 59%

$69
Average prescription price

Avg: $175

ANTON KIDESS MD

Pulmonary Disease

6,878

$419K

307
242 are 65+

10%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 59%

$61
Average prescription price

Avg: $175

KYLE DETTBARN MD

Pulmonary Disease

6,024

$550K

312
230 are 65+

9%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 59%

$91
Average prescription price

Avg: $175

FADI SABBAGH M.D.

Pulmonary Disease

4,533

$321K

366
276 are 65+

12%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 59%

$71
Average prescription price

Avg: $175

PATRICIO VIERNES M.D.

Pulmonary Disease

3,640

$286K

154
148 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 59%

$79
Average prescription price

Avg: $175

RICHARD HARBECKE M.D.

Pulmonary Disease

3,547

$289K

222
193 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 59%

$82
Average prescription price

Avg: $175

IFTEKHAR BADER M.D.

Pulmonary Disease

3,211

$335K

209
149 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 59%

$104
Average prescription price

Avg: $175

STEVEN JOHNSON MD

Pulmonary Disease

3,021

$386K

247
205 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 59%

$128
Average prescription price

Avg: $175

MARC RASANSKY MD

Pulmonary Disease

2,869

$503K

324
287 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 59%

$175
Average prescription price

Avg: $175

STEPHEN WILSON M.D.

Pulmonary Disease

2,838

$458K

330
241 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

46%
prescriptions for brand name drugs

Avg: 59%

$161
Average prescription price

Avg: $175

ADRIANE GIANLUPI MD

Pulmonary Disease

2,787

$478K

261
155 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 59%

$171
Average prescription price

Avg: $175

RICHARD CORNWELL MD

Pulmonary Disease

2,735

$320K

76
23 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 59%

$117
Average prescription price

Avg: $175

JEFFERY SMALE MD

Pulmonary Disease

2,708

$331K

358
304 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 59%

$122
Average prescription price

Avg: $175

ALFRED HABEL MD

Pulmonary Disease

2,609

$379K

310
176 are 65+

10%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 59%

$145
Average prescription price

Avg: $175

EDWARD EBERT DO

Pulmonary Disease

2,502

$299K

315
219 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 59%

$120
Average prescription price

Avg: $175

RULA AL-SAGHIR M.D.

Pulmonary Disease

2,357

$359K

312
248 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 59%

$152
Average prescription price

Avg: $175

PETER MARIANI MD

Pulmonary Disease

2,339

$194K

147
117 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 59%

$83
Average prescription price

Avg: $175

DANIEL HERRELL M.D.

Pulmonary Disease

2,265

$397K

277
246 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 59%

$175
Average prescription price

Avg: $175

JEFFREY WHITESIDE M.D.

Pulmonary Disease

2,249

$341K

274
222 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 59%

$152
Average prescription price

Avg: $175

BRYAN AVERY MD

Pulmonary Disease

2,171

$510K

299
250 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

87%
prescriptions for brand name drugs

Avg: 59%

$235
Average prescription price

Avg: $175

KENNETH PRESBERG MD

Pulmonary Disease

2,124

$1.82M

151
95 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 59%

$858
Average prescription price

Avg: $175

STEVEN KREAM MD

Pulmonary Disease

2,045

$353K

247
170 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 59%

$173
Average prescription price

Avg: $175

ROSE FRANCO MD

Pulmonary Disease

1,996

$469K

223
121 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 59%

$235
Average prescription price

Avg: $175

FRANCISCO SOTO MD

Pulmonary Disease

1,969

$1.43M

127
87 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 59%

$726
Average prescription price

Avg: $175

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank